Overview

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Status:
Completed
Trial end date:
2017-06-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of multiple ascending oral doses of ASP4345 in patients with schizophrenia. In addition, this study will evaluate the pharmacokinetics of multiple ascending oral doses of ASP4345 in patients with schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.